This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Marrone Bio Innovations Past Earnings Performance
Past criteria checks 0/6
Key information
8.4%
Earnings growth rate
51.3%
EPS growth rate
| Chemicals Industry Growth | 12.9% |
| Revenue growth rate | 22.3% |
| Return on equity | -91.3% |
| Net Margin | -47.1% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Marrone Bio Innovations makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 44 | -21 | 33 | 13 |
| 31 Dec 21 | 44 | -17 | 31 | 12 |
| 30 Sep 21 | 41 | -15 | 29 | 11 |
| 30 Jun 21 | 40 | -17 | 29 | 11 |
| 31 Mar 21 | 40 | -16 | 28 | 11 |
| 31 Dec 20 | 38 | -20 | 29 | 11 |
| 30 Sep 20 | 37 | -26 | 24 | 12 |
| 30 Jun 20 | 35 | -36 | 28 | 13 |
| 31 Mar 20 | 30 | -40 | 26 | 14 |
| 31 Dec 19 | 29 | -37 | 24 | 14 |
| 30 Sep 19 | 28 | -33 | 28 | 12 |
| 30 Jun 19 | 27 | -21 | 21 | 12 |
| 31 Mar 19 | 26 | -19 | 20 | 11 |
| 31 Dec 18 | 21 | -20 | 19 | 11 |
| 30 Sep 18 | 19 | -22 | 18 | 10 |
| 30 Jun 18 | 18 | -26 | 19 | 11 |
| 31 Mar 18 | 18 | -29 | 19 | 11 |
| 31 Dec 17 | 18 | -31 | 19 | 11 |
| 30 Sep 17 | 18 | -31 | 21 | 11 |
| 30 Jun 17 | 17 | -30 | 20 | 10 |
| 31 Mar 17 | 16 | -29 | 19 | 10 |
| 31 Dec 16 | 14 | -31 | 19 | 10 |
| 30 Sep 16 | 13 | -34 | 19 | 10 |
| 30 Jun 16 | 12 | -37 | 20 | 11 |
| 31 Mar 16 | 10 | -41 | 24 | 12 |
| 31 Dec 15 | 10 | -44 | 27 | 14 |
| 30 Sep 15 | 9 | -49 | 30 | 16 |
Quality Earnings: MBII is currently unprofitable.
Growing Profit Margin: MBII is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MBII is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare MBII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBII is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (31.5%).
Return on Equity
High ROE: MBII has a negative Return on Equity (-91.33%), as it is currently unprofitable.